Your browser doesn't support javascript.
loading
Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5­fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma.
Gong, Jun; Thomassian, Shant; Kim, Sungjin; Gresham, Gillian; Moshayedi, Natalie; Ye, Jason Y; Yang, Julianne C; Jacobs, Jonathan P; Lo, Simon; Nissen, Nick; Gaddam, Srinivas; Tighiouart, Mourad; Osipov, Arsen; Hendifar, Andrew.
Afiliación
  • Gong J; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
  • Thomassian S; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
  • Kim S; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
  • Gresham G; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
  • Moshayedi N; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
  • Ye JY; The Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
  • Yang JC; The Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
  • Jacobs JP; The Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
  • Lo S; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
  • Nissen N; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
  • Gaddam S; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
  • Tighiouart M; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
  • Osipov A; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
  • Hendifar A; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. Andrew.hendifar@cshs.org.
Sci Rep ; 12(1): 18731, 2022 Nov 04.
Article en En | MEDLINE | ID: mdl-36333397
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Sci Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Sci Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos